Objective:To evaluate placental expression and serum cytokeratin-18 in women with preeclampsia.
Methods:Serum cytokeratin-18 was evaluated in 44 women with preeclampsia and 44 healthy pregnant women using an immunoradiometric assay. Placental expression of cytokeratin-18 was investigated in specimens from 23 women with preeclampsia and 20 healthy pregnant women by immunohistochemistry.
Results:Median serum cytokeratin-18 in women with preeclampsia and healthy pregnant women was 106.7 and 76.0 U/L, respectively (P =.02). Among women with preeclampsia, serum cytokeratin-18 was significantly associated with severity of disease (P =.001) and showed a sensitivity (standard error) and specificity (standard error) of 85% (7%) and 65% (12%),respectively. In placental specimens, the cytoplasm of the syncytiotrophoblast stained positive for cytokeratin-18 with strong and widespread staining in 83% and 45% of placental specimens of women with preeclampsia and healthy pregnant women, respectively (P =.01).
Conclusion:Elevated serum cytokeratin-18 values are associated with disease severity in women with preeclampsia. OUr data provide additional evidence that the placenta might be the source of the elevated serum cytokeratin-18 values in women with preeclampsia.
1. Moll R, Franke W, Schiller D, Geiger B, Krepler R. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumours and cultured cells. Cell1982;31:11-24.
2.
2. Quinlan RA, Schiller DL, Hatzfeld M, et al. Patterns of expression and organization of cytokeratin intermediate filaments. Ann NY Acad Sci1985;455:282-306.
3.
3. Steinert PM, Idler WW, Zhou XM, et al. Structural and functional implications of amino acid sequences of keratin intermediate filament subunits. Ann NY Acad Sci1985;455:451-461.
4.
4. Gion M, Mione R, Barioli P, et al. The correlation between serum levels of cytokeratin tumor markers does reflect their molecular characterization. Int J Biol Markers1994;9:121-122.
5.
5. Sundstrom Be, Stigbrand TI. Cytokeratins and tissue polypeptide antigen. Int J Biol Markers1994;9:102-108.
6.
6. Starzinski-Powitz A, Gaetje R, Zeitvogel A, et al. Tracing cellular and molecular mechanisms involved in endometriosis. Hum Reprod Update1992;4:724-729.
7.
7. Blaheta RA, Kronenberger B, Woitaschek D, et al. Dedifferentiation of human hepatocytes by extracellular matrix proteins in vitro: Quantitative and qualitative investigation of cytokeratin 7, 8, 18, 19 and vimentin filaments. J Hepatol1998;28:677-690.
8.
8. Prochasson P, Gunther M, Leithier M, Fossar N, Lavialle C, Brison O. Transcriptional mechanisms responsible for the overexpression of the keratin 18 gene in cells of a human colon carcinoma cell line. Exp Cell Res1999;248:243-259.
9.
9. Schaller G, Fuchs I, Pritze W, et al. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res1996;2:1879-1885.
10.
10. Moll R, Levy R, Czernobilsky B, Hohlweg-Majert P, Dallenbach-Hellweg G, Franke WW. Cytokeratins of normal epithelia and some neoplasms of the female genital tract. Lab Invest1983;49:599-610.
11.
11. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E. A Prospective study fo serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. Br J Cancer1994;69:562-565.
12.
12. Kramer G, Steiner GE, Madersbacher S, Stulnig T, Lang T, Marberger M, Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate. J Urol1997;158:1446-1451.
13.
13. Suzuki S, Furukawa H, Tsuchiya A. Clinical evaluation of serum tissue polypeptide specific antigen in patients with thyroid carcinoma. Thyroid1999;9:921-925.
14.
14. Gaarenstroom KN, Bonfrer JM, Kenter GG, et al. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Cancer1995;76:807-813.
15.
15. Tempfer C, Hefler L, Haeusler G, et al. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients. Int J Cancer1998;79:241-244.
16.
16. Schrocksnadel H, Daxenbichler G, Artner E, Steckel-Berger G, Dapunt O. Tissue polypeptide antigen and pre-eclampsia. Lancet1992;340:53-54.
17.
17. Kertesz L, Sargent I, Redman C. Tissue polypeptide antigen (TPA) in preeclampsia. J Soc Gynecol Investig1997;4:193-193.
18.
18. Chua S, Wilkins T, Sargent I, Redman C. Trophoblast deportation in pre-eclamptic pregnancy. Br. J Obstet Gynaecol1991;98:973-979.
19.
19. Redline R, Patterson P. Pre-eclampsia is associated with an excess of proliferative immature intermediate trophoblast. Hum Pathol1995;26:594-600.
20.
20. Tempfer CB, Bancher-Todesca D, Zeisler H, Schatten C, Husslain P, Gregg AR. Placental expression and serum concentrations of cytokeratin 19 in preeclampsia. Obstet Gynecol2000;95:677-682.
21.
21. Anonymous. National High Blood Pressure Education Programme Working Group Report on High Blood Pressure in Pregnancy. U.S. Department of Health and Human Services 1991. NIH Pub. No. 91.
22.
22. Cunningham FG, MacDonald PC, Gant NF, Leveno KJ, Gilstrap LC, Hankins GD, et al. Williams Obstetrics, 20th ed.Norwalk: Appleton and Lange, 1997:695-696.
23.
23. Stiemer B, Graf R, Neudeck H, Hildebrandt R, Hopp H, Weitzel H. Antibodies to cytokeratins bind to epitopes in human uterine smooth muscle cells in normal and pathological pregnancies. Histopathology1995;27:407-414.
24.
24. Daya D, Sabet LThe use of cytokeratin as a sensitive and reliable markeer for trophoblastic tissue. Am J Clin Pathol1991;95:137-141.
25.
25. Bremme K, Eneroth P, Nilsson B, Olsson M. Maternal and cord serum levels of tissue polypeptide antigen (TPA) in normal pregnancies. Gynecol Obstet Invest1985;19:118-123.
26.
26. Einarsson R, Rydlander L. Tissue polypeptide specific antigen (TPS) detects a specific epitope structure on human cytokeratin. Anticancer Res1997;17:3121-3124.
27.
27. Rydlander L, Ziegler E, Bergman T, et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem1996;241:309-314.
28.
28. Hefler L, Tempfer C, Heinzl H, et al. M3/M21 serum levels in women with adnexal masses and inflammatory diseases. Int J Cancer1998;79:434-438.
29.
29. McCowan LM, Buist RG, North RA, Gamble G. Perinatal morbidity in chronic hypertension. Br J Obstet Gynaecol1996;103:123-129.
30.
30. Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol1990;163:1049-1054.
